Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes.
Oka
Satoko
S
Muroi
Kazuo
K
Mori
Masaki
M
Matsuyama
Tomohiro
T
Fujiwara
Shin-ichiro
S
Oh
Iekuni
I
Sato
Kazuya
K
Kikuchi
Satoru
S
Ueda
Masuzu
M
Toshima
Masaki
M
Suzuki
Takahiro
T
Ozaki
Katsutoshi
K
Nagai
Tadashi
T
Ozawa
Keiya
K
D000328:Adult; D000368:Aged; D000941:Antigens / Q000276:immunology; D001549:Benzamides; D001854:Bone Marrow Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000941:Antigens; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate